Cumberland Pharmaceuticals reported that ifetroban was well tolerated in a Phase 2a trial involving patients with systemic sclerosis (SSc), a rare autoimmune disease causing fibrosis and organ issues. The 12-month trial showed no serious drug-related adverse events, supporting ifetroban's safety profile. While the trial was not designed to prove efficacy, ongoing biomarker and cardiac imaging studies will guide further development. This is significant as no approved treatments currently target the primary cardiac complications of SSc, a leading cause of mortality in these patients.
Cumberland Pharmaceuticals' ASSIST-SSc trial results provide context for readers interested in health sector developments. As of Oct 24, 2026 03:11 WIB, among 150 health-sector US stocks on Pluang, 62 advanced while 88 declined. Notably, Enveric Biosciences Inc (ENVB) traded at USD 1.38 with a 5.48% drop, Amylx Pharmaceuticals Inc (AMLX) was at USD 27.26 down 4.59%, and Illumina, Inc. (ILMN) stood at USD 270.00, falling 4.55%, with typical hold times ranging from 14 to 84 days on Pluang.
Remittix has raised $33 million and will burn 300 million RTX tokens, reducing supply by 20% ahead of public trading starting November 24, 2026. This token burn and near-cap funding boost scarcity and investor interest. Meanwhile, the XRP Ledger's No...
XTransfer, a leading global B2B cross-border payment platform, made its first appearance at Money20/20 USA 2026 in Las Vegas to accelerate its expansion into Latin American markets. The company recently completed regulatory registration in Chile, ena...
Kelvin Veras Real Estate completed 16 real estate transactions in its first year operating in New Jersey, including sales, purchases, rentals, and landlord services. This milestone highlights the company's successful market entry and diverse client s...
The documentary 'NURSE: Empathy Heals' premiered on October 21 in Nashville, showcasing personal stories of nurses and the critical role of empathy in healthcare. It highlights the emotional challenges nurses face, especially during crises like the C...
Oxford Square Capital Corp. announced it will hold a conference call on October 30, 2026, at 9:00 AM Eastern time to discuss its third quarter 2026 earnings. Investors can join the call via a toll-free number, and a recorded replay will be available ...
